Stablepharma has announced the appointment of Dr. Kenny Simmen as its Chief Business Officer, effective March 1, 2025. Following a year of service on the company’s Advisory Board, Dr. Simmen will now lead Stablepharma’s business development efforts, including partnering and licensing activities, as part of the company’s ambitious growth strategy.
Dr Simmen has 30 years of global pharmaceutical experience, with a successful track record in drug discovery/early clinical development and innovative collaboration and dealmaking, which brings invaluable expertise to Stablepharma’s Executive Team.
“We are delighted that Kenny has agreed to take on this crucial role, especially as we approach the commercialisation of our first fridge-free vaccine, SPVX02—an adult booster for the prevention of Tetanus diphtheria,” said Ozgur Tuncer, CEO & Executive Director of Stablepharma. “Stablepharma is forging key partnerships with global vaccine manufacturers, CDMOs, academic institutions, and NGOs, and Kenny’s expertise is hugely advantageous to us, as we continue advancing our pipeline of thermostable products.”
As part of the J&J Infectious Diseases & Vaccines leadership team, Dr Simmen previously led the establishment of many international collaborations & license agreements with biotechs and leading academic teams in the US, Europe and Asia. He will work closely with the science and commercial teams to explore R&D partnerships and licensing deals that will form part of Stablepharma’s growing fridge-free pharmaceutical pipeline.
Stablepharma’s groundbreaking technology platform, StablevaX™, transforms vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing a critical global challenge: the distribution, storage, and wastage issues associated with temperature-sensitive products reliant on the cold chain.
“Stablepharma’s innovative fridge-free technology, StablevaX™, caught my attention a few years ago. The company’s mission to reduce cold chain waste and deliver improved healthcare outcomes worldwide is a vision I’m keen to support,” said Dr. Simmen.
Stablepharma was recently awarded €2.5 million through the prestigious European Innovation Council (EIC) Accelerator program for its cutting-edge fridge-free pharmaceutical technology Stablepharma Secures €2.5m EIC Grant, recognised Among Europe’s Top 71 Innovators – Stablepharma